北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于深圳市德方纳米科技股份有限公司 2023 年度向不特定对象发行可转换公司债券的 补充法律意见书（一） 致：深圳市德方纳米科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受深圳市德方纳米科技股份 有限公司（以下简称"发行人"或"公司"）委托，担任德方纳米 2023 年度向不 特定对象发行可转换公司债券（以下简称"本次发行"）的专项法律顾问。 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）等有关法律、行政法规和中国证券监督管理委 员会（以下简称"中国证监会"）颁布的《可转换公司 ...

（深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 深圳市德方纳米科技股份有限公司 （Shenzhen Dynanonic Co., Ltd.） （深圳市南山区桃源街道福光社区留仙大道 3370 号南山智园崇文园区 1 号楼 1001） 2023 年度向不特定对象发行可转换公司债券 并在创业板上市 募集说明书 保荐人（主承销商） 重大事项提示 2023 年 8 月 股票简称：德方纳米 股票代码：300769 深圳市德方纳米科技股份有限公司 募集说明书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1-1-1 深圳市德方纳米科技股份有限公司 募集说明书 公司聘请中证鹏元资信评估股份 ...

华泰联合证券有限责任公司 关于深圳市德方纳米科技股份有限公司 2023 年度向不特定对象发行可转换公司 债券并在创业板上市之 发行保荐书 保荐人（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 发行保荐书 华泰联合证券有限责任公司 关于深圳市德方纳米科技股份有限公司 2023 年度向不特定对象发行可转换公司债券 并在创业板上市之发行保荐书 深圳市德方纳米科技股份有限公司（以下简称"发行人"、"公司"、"德方纳 米"）申请向不特定对象发行可转换公司债券并在创业板上市，依据《公司法》 《证券法》《上市公司证券发行注册管理办法》（以下简称"《再融资注册办法》"） 等相关的法律、法规的有关规定，提交发行申请文件。华泰联合证券有限责任公 司（以下简称"华泰联合证券"、"保荐人"）作为其本次发行的保荐人，肖耿豪和 董瑞超作为具体负责推荐的保荐代表人，特为其出具本发行保荐书。 保荐人华泰联合证券、保荐代表人肖耿豪和董瑞超承诺：本保荐人和保荐代 表人根据《公司法》《证券法》等有关法律、法规和中国证监会、深圳证券交易 所的有关规定，诚实守信、勤勉尽责，严格按照依法制定的业务规则、行业执 ...

上市保荐书 华泰联合证券有限责任公司关于 深圳市德方纳米科技股份有限公司 2023 年度向不特定对象 发行可转换公司债券并在创业板上市之上市保荐书 深圳证券交易所： 作为深圳市德方纳米科技股份有限公司（以下简称"发行人"、"公司"） 2023 年度向不特定对象发行可转换公司债券并在创业板上市的保荐人，华泰联 合证券有限责任公司及其保荐代表人已根据《中华人民共和国公司法》（以下简 称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）《上市公司证券 发行注册管理办法》（以下简称"《再融资注册办法》"）等法律法规和中国证 券监督管理委员会（以下简称中国证监会）及贵所的有关规定，诚实守信，勤勉 尽责，严格按照依法制定的业务规则和行业自律规范出具上市保荐书，并保证所 出具文件真实、准确、完整。 现将有关情况报告如下： 一、发行人基本情况 （一）发行人概况 发行人名称：深圳市德方纳米科技股份有限公司 注册地址：深圳市南山区桃源街道福光社区留仙大道 3370 号南山智园崇文 园区 1 号楼 1001 注册时间：2007 年 1 月 25 日 联系方式：86-0755-26918296 （二）发行人的主营业务 公司 ...

关于深圳市德方纳米科技股份有限公司 申请向不特定对象发行可转换公司债券 审核问询函的回复报告 （修订稿） 保荐人（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 深圳市德方纳米科技股份有限公司 审核问询函的回复报告 深圳证券交易所： 贵所于 2023 年 5 月 10 日出具的《关于深圳市德方纳米科技股份有限公司申 请向不特定对象发行可转换公司债券的审核问询函》（审核函〔2023〕020079 号） （以下简称"审核问询函"）已收悉。深圳市德方纳米科技股份有限公司（以下 简称"公司"、"德方纳米"或"发行人"）与华泰联合证券有限责任公司（以下 简称"保荐人"）、北京市中伦律师事务所（以下简称"发行人律师"）、容诚会计 师事务所（特殊普通合伙）（以下简称"发行人会计师"）等相关方对审核问询函 所列问题进行了核查，对申请材料认真地进行了修改、补充和说明。现对问询函 的落实和募集说明书的修改情况逐条书面回复，并提交贵所，请予审核。 说明： 1、如无特殊说明，本回复报告中使用的简称或名词释义与《深圳市德方纳 米科技股份有限公司向不特定对象发行可转换公司债券并在创业板上市募集说 ...

Group 1: Financial Performance - The company expects a loss of 1.04 to 1.17 billion in the first half of 2023, with a reduction in losses in the second quarter compared to the first quarter [2] - Sales revenue and volume of products achieved year-on-year growth in the first half of 2023 [2][3] Group 2: Market Conditions - The decline in sales prices was influenced by a significant drop in lithium salt prices and a slowdown in downstream demand [3] - The company's production capacity utilization rate began to recover in May 2023, reaching full production and sales in June [3][4] Group 3: Product Development - The company has made progress in its new product, lithium manganese phosphate, which is expected to ramp up production in the second half of 2023 [4] - The company has built a production capacity of 110,000 tons for lithium manganese phosphate, leading in scale and capability for mass production [4] Group 4: Strategic Initiatives - The company is focusing on deepening cooperation with existing customers while also developing new clients to optimize customer structure and increase sales [5] - A strategy to reduce costs and enhance internal efficiency is being implemented to improve profitability [5]

Financial Performance - The company's operating revenue for Q1 2023 was ¥4,944,745,935.53, representing a 46.56% increase compared to ¥3,373,860,080.51 in the same period last year[4] - The net profit attributable to shareholders was -¥717,334,775.51, a decrease of 194.17% from ¥761,713,535.71 in the previous year[4] - The net cash flow from operating activities improved by 54.64%, amounting to -¥783,419,218.59, compared to -¥1,727,195,118.12 in the same period last year[4] - The weighted average return on equity was -8.46%, a significant decline from 21.64% in the same period last year[4] - The company reported a basic earnings per share of -¥4.14, a decrease of 187.34% from ¥4.74 in the previous year[4] - The total operating revenue for the first quarter of 2023 was CNY 4,944,745,935.53, an increase from CNY 3,373,860,080.51 in the same period last year, representing a growth of approximately 46.7%[56] - The total operating costs for the first quarter of 2023 were CNY 5,295,603,524.53, up from CNY 2,468,714,654.32 in the previous year, indicating an increase of about 114%[56] - The company's net profit for the first quarter was not explicitly stated, but the retained earnings decreased to CNY 2,721,020,915.40 from CNY 3,438,355,690.91, a decline of about 20.9%[56] - The net profit for the current period is -907,989,332.91 CNY, compared to a net profit of 775,868,515.18 CNY in the previous period, indicating a significant decline[57] - The total comprehensive income for the current period is -951,675,795.14 CNY, while it was 775,868,515.18 CNY in the previous period, reflecting a substantial decrease[58] - The operating profit for the current period is -1,055,902,238.41 CNY, compared to an operating profit of 906,760,302.45 CNY in the previous period[57] Assets and Liabilities - Total assets at the end of the reporting period were ¥27,106,275,767.79, down 6.83% from ¥29,094,244,309.19 at the end of the previous year[4] - The company’s total equity attributable to shareholders decreased by 7.60%, amounting to ¥8,143,100,322.98 compared to ¥8,813,064,394.06 at the end of the previous year[4] - The total liabilities decreased to CNY 17,253,884,018.08 from CNY 18,434,905,235.70, reflecting a reduction of approximately 6.4%[54] - The company's cash and cash equivalents decreased to CNY 2,825,008,779.66 from CNY 3,513,218,178.72, a decline of approximately 19.6%[51] - The company's total assets at the end of the period amount to 2,052,682,755.82 CNY, compared to 1,063,431,953.95 CNY at the end of the previous period[60] Cash Flow - Cash flow from operating activities shows a net outflow of -783,419,218.59 CNY, improving from -1,727,195,118.12 CNY in the previous period[59] - Cash flow from investing activities results in a net outflow of -730,915,260.27 CNY, compared to -1,157,843,201.63 CNY in the previous period[59] - Cash flow from financing activities shows a net inflow of 1,286,018,848.44 CNY, down from 2,685,485,440.52 CNY in the previous period[60] - The company reported a significant increase in cash received from sales, totaling 2,102,585,131.06 CNY, compared to 558,381,586.25 CNY in the previous period[58] Investments and Financing - The company signed an investment agreement for a new production base with an annual capacity of 110,000 tons of new phosphate-based cathode materials, with a total investment of approximately CNY 2.5 billion[27] - The company plans to raise up to CNY 3.5 billion through a convertible bond issuance to fund the new production base and supplement working capital[28] - Long-term borrowings increased by 76.39% to CNY 4,370,786,030.72, primarily due to increased bank financing during the reporting period[17] - The company issued convertible bonds to unspecified investors, although details regarding the amount and terms were not disclosed in the report[49] Accounts Receivable and Inventory - Accounts receivable decreased by 39.87% to CNY 2,625,490,208.92 due to the collection of overdue payments during the reporting period[17] - Inventory decreased by 51.43% to CNY 2,493,218,454.20 as a result of reduced inventory levels at the end of the reporting period[17] - Accounts receivable dropped to CNY 2,625,490,208.92 from CNY 4,366,709,990.97, a decrease of about 40%[51] Research and Development - Research and development expenses increased by 30.40% to CNY 130,675,217.11, attributed to higher share-based payment expenses and R&D materials[42] - Research and development expenses increased to CNY 130,675,217.11 from CNY 100,214,402.29, marking a rise of approximately 30.3%[56] Shareholder Information - The company’s major shareholder, Ji Xuewen, holds 13.99% of the shares, with a total of 24,311,040 shares[9] Credit and Impairment - The company reported a significant increase in credit impairment losses, which rose by 1944.60% due to a decrease in accounts receivable[8] - Deferred tax assets increased by 60.34% to CNY 392,993,581.64 due to provisions for inventory impairment during the reporting period[17]

关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300769 证券简称：德方纳米 公告编号：2023-043 深圳市德方纳米科技股份有限公司 1、召开时间：2023年4月28日（星期五）下午15:00–17:00 2、召开地点：价值在线（www.ir-online.cn） 3、召开方式：网络互动方式 二、公司出席人员 公司董事长兼总经理孔令涌先生、财务总监林旭云女士、董事会秘书何艳艳 女士、独立董事毕晓婷女士、保荐代表人董瑞超先生。 深圳市德方纳米科技股份有限公司（以下简称"公司"）于2023年3月31日 在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022年年度报告》及《2022 年年度报告摘要》。为了便于广大投资者进一步了解公司2022年年度经营情况， 公司定于2023年4月28日（星期五）通过"价值在线"（www.ir-online.cn）举办 2022年度网上业绩说明会。现将具体情况公告如下： 一、本次业绩说明会召开的时间、地点和方式 三、投资者参与方式 投资者可于 20 ...